| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 198 | 2025 | 1260 | 20.810 |
Why?
|
| HIV Antibodies | 114 | 2025 | 247 | 17.780 |
Why?
|
| Antibodies, Neutralizing | 91 | 2025 | 303 | 13.550 |
Why?
|
| HIV Infections | 184 | 2025 | 5097 | 9.320 |
Why?
|
| HIV Envelope Protein gp120 | 50 | 2022 | 104 | 6.630 |
Why?
|
| AIDS Vaccines | 40 | 2023 | 152 | 6.170 |
Why?
|
| Drug Resistance, Viral | 49 | 2025 | 278 | 5.800 |
Why?
|
| Epitopes | 39 | 2024 | 97 | 3.920 |
Why?
|
| Humans | 234 | 2025 | 14537 | 3.640 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 28 | 2025 | 52 | 3.630 |
Why?
|
| Antibodies, Monoclonal | 31 | 2025 | 142 | 2.900 |
Why?
|
| Anti-HIV Agents | 40 | 2020 | 1324 | 2.570 |
Why?
|
| Neutralization Tests | 46 | 2021 | 108 | 2.530 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 9 | 2022 | 36 | 2.380 |
Why?
|
| HIV Envelope Protein gp41 | 17 | 2022 | 28 | 2.290 |
Why?
|
| HIV Envelope Protein gp160 | 8 | 2021 | 22 | 2.250 |
Why?
|
| Polysaccharides | 8 | 2023 | 45 | 2.180 |
Why?
|
| Reverse Transcriptase Inhibitors | 13 | 2020 | 118 | 2.140 |
Why?
|
| Immunoglobulin G | 17 | 2022 | 231 | 2.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2021 | 151 | 1.960 |
Why?
|
| Viral Load | 37 | 2023 | 819 | 1.840 |
Why?
|
| Female | 106 | 2025 | 9103 | 1.830 |
Why?
|
| Molecular Sequence Data | 43 | 2015 | 263 | 1.670 |
Why?
|
| HIV Seropositivity | 11 | 2024 | 265 | 1.620 |
Why?
|
| Single-Chain Antibodies | 3 | 2021 | 5 | 1.560 |
Why?
|
| RNA, Viral | 23 | 2019 | 303 | 1.550 |
Why?
|
| Amino Acid Sequence | 34 | 2020 | 139 | 1.540 |
Why?
|
| Peptide Fragments | 14 | 2018 | 37 | 1.510 |
Why?
|
| Lectins | 4 | 2013 | 8 | 1.480 |
Why?
|
| Antibody Specificity | 12 | 2020 | 30 | 1.420 |
Why?
|
| Mutation | 31 | 2025 | 306 | 1.420 |
Why?
|
| Integrins | 4 | 2020 | 9 | 1.390 |
Why?
|
| B-Lymphocytes | 10 | 2021 | 34 | 1.350 |
Why?
|
| HIV Protease | 10 | 2019 | 22 | 1.270 |
Why?
|
| Adult | 53 | 2025 | 5913 | 1.270 |
Why?
|
| Receptors, HIV | 6 | 2018 | 12 | 1.250 |
Why?
|
| Nevirapine | 15 | 2012 | 146 | 1.220 |
Why?
|
| HIV Protease Inhibitors | 10 | 2019 | 92 | 1.210 |
Why?
|
| Genotype | 22 | 2020 | 442 | 1.120 |
Why?
|
| Carrier Proteins | 3 | 2013 | 23 | 1.110 |
Why?
|
| Genitalia, Female | 2 | 2019 | 17 | 1.110 |
Why?
|
| Epitope Mapping | 18 | 2021 | 32 | 1.090 |
Why?
|
| Male | 56 | 2025 | 6754 | 1.080 |
Why?
|
| Virus Replication | 12 | 2021 | 88 | 1.070 |
Why?
|
| Algal Proteins | 3 | 2011 | 4 | 1.060 |
Why?
|
| HIV | 12 | 2019 | 380 | 1.050 |
Why?
|
| Phylogeny | 24 | 2021 | 231 | 1.050 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 119 | 1.040 |
Why?
|
| Immunization, Passive | 5 | 2021 | 17 | 1.020 |
Why?
|
| South Africa | 62 | 2025 | 7596 | 1.020 |
Why?
|
| CD4 Antigens | 10 | 2025 | 49 | 1.000 |
Why?
|
| Animals | 26 | 2023 | 1081 | 0.940 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2021 | 22 | 0.920 |
Why?
|
| Sequence Analysis, DNA | 24 | 2019 | 181 | 0.920 |
Why?
|
| Protein Binding | 16 | 2021 | 62 | 0.890 |
Why?
|
| Antibodies, Viral | 8 | 2025 | 284 | 0.890 |
Why?
|
| Cell Line | 17 | 2021 | 93 | 0.870 |
Why?
|
| Acquired Immunodeficiency Syndrome | 9 | 2023 | 187 | 0.850 |
Why?
|
| Receptors, CXCR4 | 9 | 2014 | 28 | 0.850 |
Why?
|
| Antiretroviral Therapy, Highly Active | 12 | 2019 | 472 | 0.850 |
Why?
|
| Vagina | 5 | 2019 | 91 | 0.840 |
Why?
|
| Binding Sites, Antibody | 5 | 2017 | 8 | 0.840 |
Why?
|
| Cross Reactions | 13 | 2021 | 44 | 0.790 |
Why?
|
| HIV Reverse Transcriptase | 9 | 2015 | 41 | 0.780 |
Why?
|
| Gene Products, gag | 4 | 2016 | 11 | 0.760 |
Why?
|
| Receptors, CCR5 | 11 | 2016 | 54 | 0.740 |
Why?
|
| Viremia | 9 | 2019 | 66 | 0.730 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 6 | 2022 | 8 | 0.720 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2018 | 9 | 0.720 |
Why?
|
| Antiviral Agents | 2 | 2013 | 111 | 0.710 |
Why?
|
| Organophosphonates | 4 | 2015 | 45 | 0.700 |
Why?
|
| Virion | 4 | 2018 | 12 | 0.700 |
Why?
|
| Plant Lectins | 4 | 2013 | 5 | 0.690 |
Why?
|
| Immune Evasion | 7 | 2021 | 31 | 0.680 |
Why?
|
| Adenine | 4 | 2015 | 91 | 0.680 |
Why?
|
| Flow Cytometry | 2 | 2018 | 67 | 0.670 |
Why?
|
| Antibody Formation | 8 | 2020 | 61 | 0.660 |
Why?
|
| Genes, env | 4 | 2009 | 9 | 0.650 |
Why?
|
| Gene Products, env | 5 | 2009 | 11 | 0.650 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2019 | 4 | 0.650 |
Why?
|
| Infectious Disease Transmission, Vertical | 11 | 2019 | 472 | 0.650 |
Why?
|
| Phenotype | 11 | 2025 | 158 | 0.640 |
Why?
|
| Young Adult | 19 | 2025 | 2498 | 0.640 |
Why?
|
| Mutation, Missense | 8 | 2016 | 65 | 0.610 |
Why?
|
| Lysine | 1 | 2018 | 5 | 0.600 |
Why?
|
| Cohort Studies | 16 | 2020 | 967 | 0.600 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2019 | 198 | 0.600 |
Why?
|
| Disease Progression | 12 | 2019 | 154 | 0.600 |
Why?
|
| Immunization, Secondary | 5 | 2021 | 72 | 0.590 |
Why?
|
| Simian Immunodeficiency Virus | 5 | 2022 | 8 | 0.580 |
Why?
|
| Middle Aged | 20 | 2025 | 3601 | 0.580 |
Why?
|
| Polymorphism, Genetic | 5 | 2024 | 99 | 0.570 |
Why?
|
| Longitudinal Studies | 9 | 2019 | 435 | 0.560 |
Why?
|
| HIV Fusion Inhibitors | 3 | 2012 | 5 | 0.560 |
Why?
|
| Epitopes, B-Lymphocyte | 4 | 2022 | 7 | 0.550 |
Why?
|
| Infant | 19 | 2019 | 2244 | 0.550 |
Why?
|
| Genetic Variation | 9 | 2021 | 175 | 0.550 |
Why?
|
| Host-Pathogen Interactions | 3 | 2020 | 24 | 0.530 |
Why?
|
| HEK293 Cells | 8 | 2021 | 39 | 0.520 |
Why?
|
| Adolescent | 17 | 2025 | 2985 | 0.520 |
Why?
|
| Lopinavir | 7 | 2019 | 137 | 0.510 |
Why?
|
| Treatment Failure | 9 | 2017 | 175 | 0.500 |
Why?
|
| Genes, Immunoglobulin | 2 | 2016 | 5 | 0.500 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2024 | 8 | 0.480 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2025 | 101 | 0.470 |
Why?
|
| Germ Cells | 1 | 2015 | 9 | 0.470 |
Why?
|
| Anti-Retroviral Agents | 6 | 2015 | 551 | 0.460 |
Why?
|
| Binding Sites | 8 | 2018 | 43 | 0.460 |
Why?
|
| Viral Envelope Proteins | 4 | 2018 | 6 | 0.450 |
Why?
|
| HIV Antigens | 7 | 2020 | 26 | 0.430 |
Why?
|
| CD4 Lymphocyte Count | 15 | 2019 | 656 | 0.420 |
Why?
|
| Pregnancy | 17 | 2019 | 1862 | 0.410 |
Why?
|
| Superinfection | 3 | 2018 | 8 | 0.410 |
Why?
|
| Vaccines, DNA | 3 | 2019 | 11 | 0.410 |
Why?
|
| Receptors, IgG | 4 | 2022 | 28 | 0.400 |
Why?
|
| Polymerase Chain Reaction | 9 | 2014 | 260 | 0.400 |
Why?
|
| Evolution, Molecular | 6 | 2016 | 60 | 0.400 |
Why?
|
| Time Factors | 12 | 2017 | 507 | 0.390 |
Why?
|
| Amino Acid Substitution | 6 | 2016 | 35 | 0.380 |
Why?
|
| Models, Molecular | 10 | 2019 | 84 | 0.380 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2020 | 150 | 0.380 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 4 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 7 | 0.370 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 7 | 0.370 |
Why?
|
| Down-Regulation | 1 | 2011 | 22 | 0.370 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 2 | 0.360 |
Why?
|
| Antibodies | 2 | 2009 | 25 | 0.360 |
Why?
|
| Child, Preschool | 9 | 2019 | 1748 | 0.360 |
Why?
|
| Alleles | 5 | 2024 | 143 | 0.360 |
Why?
|
| Child | 9 | 2019 | 2242 | 0.350 |
Why?
|
| Glycosylation | 6 | 2017 | 17 | 0.340 |
Why?
|
| Ritonavir | 5 | 2016 | 137 | 0.340 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2016 | 14 | 0.340 |
Why?
|
| Tenofovir | 6 | 2018 | 171 | 0.340 |
Why?
|
| Mannose | 1 | 2010 | 5 | 0.330 |
Why?
|
| Base Sequence | 7 | 2015 | 149 | 0.330 |
Why?
|
| Protein Conformation | 6 | 2018 | 24 | 0.320 |
Why?
|
| Sequence Alignment | 9 | 2017 | 59 | 0.320 |
Why?
|
| Heteroduplex Analysis | 2 | 2006 | 4 | 0.320 |
Why?
|
| Genes, gag | 2 | 2006 | 6 | 0.320 |
Why?
|
| Patient Compliance | 6 | 2014 | 120 | 0.310 |
Why?
|
| Genotyping Techniques | 4 | 2016 | 38 | 0.300 |
Why?
|
| Disease Transmission, Infectious | 3 | 2018 | 39 | 0.300 |
Why?
|
| Immunoglobulin Variable Region | 4 | 2024 | 9 | 0.300 |
Why?
|
| Vaccination | 8 | 2022 | 365 | 0.290 |
Why?
|
| National Health Programs | 2 | 2008 | 78 | 0.280 |
Why?
|
| Membrane Proteins | 3 | 2013 | 36 | 0.280 |
Why?
|
| Complementarity Determining Regions | 5 | 2022 | 11 | 0.270 |
Why?
|
| Sequence Analysis, RNA | 6 | 2018 | 17 | 0.270 |
Why?
|
| Genetic Engineering | 3 | 2021 | 7 | 0.270 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 20 | 0.270 |
Why?
|
| Genes, nef | 1 | 2007 | 2 | 0.270 |
Why?
|
| HIV-2 | 3 | 2015 | 15 | 0.270 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2021 | 19 | 0.260 |
Why?
|
| Protein Structure, Tertiary | 6 | 2014 | 22 | 0.260 |
Why?
|
| Recombination, Genetic | 3 | 2011 | 27 | 0.260 |
Why?
|
| Prospective Studies | 10 | 2021 | 1160 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 21 | 0.260 |
Why?
|
| Serotyping | 1 | 2006 | 66 | 0.260 |
Why?
|
| Crystallography, X-Ray | 5 | 2017 | 12 | 0.260 |
Why?
|
| Prenatal Care | 1 | 2008 | 147 | 0.250 |
Why?
|
| Macaca mulatta | 7 | 2022 | 14 | 0.250 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2006 | 56 | 0.250 |
Why?
|
| Infant, Newborn | 9 | 2019 | 1479 | 0.240 |
Why?
|
| DNA Primers | 5 | 2011 | 55 | 0.240 |
Why?
|
| Peptides | 2 | 2018 | 40 | 0.240 |
Why?
|
| Protein Multimerization | 4 | 2020 | 8 | 0.240 |
Why?
|
| THP-1 Cells | 3 | 2021 | 6 | 0.240 |
Why?
|
| Selection, Genetic | 4 | 2016 | 31 | 0.230 |
Why?
|
| Polysorbates | 3 | 2021 | 10 | 0.230 |
Why?
|
| Squalene | 3 | 2021 | 10 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2009 | 529 | 0.230 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 22 | 0.230 |
Why?
|
| Developing Countries | 2 | 2008 | 400 | 0.230 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2007 | 27 | 0.220 |
Why?
|
| Drug Administration Schedule | 7 | 2011 | 156 | 0.220 |
Why?
|
| Herpesvirus 8, Human | 2 | 2003 | 14 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2022 | 48 | 0.220 |
Why?
|
| Piperazines | 1 | 2004 | 82 | 0.220 |
Why?
|
| SAIDS Vaccines | 2 | 2021 | 4 | 0.210 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 2011 | 5 | 0.210 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 65 | 0.210 |
Why?
|
| Biomarkers | 2 | 2022 | 327 | 0.210 |
Why?
|
| Serial Passage | 3 | 2021 | 5 | 0.210 |
Why?
|
| Double-Blind Method | 6 | 2021 | 272 | 0.210 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2014 | 195 | 0.210 |
Why?
|
| Virus Internalization | 3 | 2014 | 5 | 0.200 |
Why?
|
| Single-Cell Analysis | 2 | 2019 | 3 | 0.200 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2018 | 24 | 0.200 |
Why?
|
| Receptors, Cytokine | 1 | 2002 | 1 | 0.200 |
Why?
|
| Hepatitis C | 1 | 2023 | 37 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2018 | 889 | 0.190 |
Why?
|
| Immunoglobulin A | 3 | 2022 | 39 | 0.190 |
Why?
|
| Germinal Center | 2 | 2019 | 3 | 0.190 |
Why?
|
| Adjuvants, Immunologic | 2 | 2018 | 23 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 12 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2022 | 480 | 0.180 |
Why?
|
| Immunization | 5 | 2021 | 63 | 0.180 |
Why?
|
| Tuberculosis | 2 | 2004 | 543 | 0.180 |
Why?
|
| Protease Inhibitors | 2 | 2011 | 23 | 0.170 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 6 | 0.170 |
Why?
|
| Aptamers, Nucleotide | 2 | 2012 | 3 | 0.170 |
Why?
|
| World Health Organization | 3 | 2019 | 137 | 0.170 |
Why?
|
| Plasma | 4 | 2019 | 39 | 0.170 |
Why?
|
| Coinfection | 1 | 2023 | 276 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2021 | 104 | 0.170 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2018 | 13 | 0.170 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 3 | 0.170 |
Why?
|
| Antitubercular Agents | 1 | 2003 | 322 | 0.170 |
Why?
|
| Genes, pol | 2 | 2013 | 4 | 0.170 |
Why?
|
| Tobacco | 1 | 2020 | 14 | 0.160 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2020 | 10 | 0.160 |
Why?
|
| Antibodies, Blocking | 2 | 2016 | 9 | 0.160 |
Why?
|
| Receptors, Fc | 1 | 2019 | 10 | 0.160 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2019 | 7 | 0.160 |
Why?
|
| Vaccinia | 2 | 2016 | 3 | 0.160 |
Why?
|
| Interleukin-5 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2019 | 26 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 10 | 0.160 |
Why?
|
| Specimen Handling | 3 | 2015 | 105 | 0.160 |
Why?
|
| Reproductive Tract Infections | 1 | 2019 | 8 | 0.160 |
Why?
|
| Gene Expression | 2 | 2016 | 43 | 0.160 |
Why?
|
| Vaccinia virus | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mutagenesis, Insertional | 1 | 2019 | 8 | 0.150 |
Why?
|
| Darunavir | 1 | 2019 | 12 | 0.150 |
Why?
|
| Introns | 1 | 2018 | 13 | 0.150 |
Why?
|
| Exons | 1 | 2018 | 17 | 0.150 |
Why?
|
| Tissue Donors | 1 | 2018 | 17 | 0.150 |
Why?
|
| Cells, Cultured | 6 | 2019 | 79 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 7 | 0.150 |
Why?
|
| Genome, Viral | 2 | 2012 | 64 | 0.140 |
Why?
|
| Gene Frequency | 4 | 2007 | 122 | 0.140 |
Why?
|
| Prevalence | 5 | 2019 | 1192 | 0.140 |
Why?
|
| Meningitis | 1 | 1998 | 26 | 0.140 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.140 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 1422 | 0.140 |
Why?
|
| Cluster Analysis | 4 | 2013 | 65 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2015 | 799 | 0.140 |
Why?
|
| Glycopeptides | 1 | 2017 | 1 | 0.130 |
Why?
|
| Molecular Mimicry | 1 | 2017 | 2 | 0.130 |
Why?
|
| Clonal Deletion | 1 | 2017 | 1 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Phagocytosis | 3 | 2021 | 15 | 0.130 |
Why?
|
| Kinetics | 3 | 2011 | 65 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 101 | 0.130 |
Why?
|
| Vaginal Douching | 1 | 2016 | 8 | 0.130 |
Why?
|
| Cell Separation | 2 | 2017 | 6 | 0.130 |
Why?
|
| Antigenic Variation | 4 | 2018 | 7 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 385 | 0.120 |
Why?
|
| Blood Donors | 2 | 2021 | 19 | 0.120 |
Why?
|
| Virus Attachment | 1 | 2015 | 1 | 0.120 |
Why?
|
| Immunization Schedule | 1 | 2016 | 81 | 0.120 |
Why?
|
| Desiccation | 1 | 2015 | 15 | 0.120 |
Why?
|
| Body Fluids | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2015 | 22 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2018 | 60 | 0.120 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 52 | 0.120 |
Why?
|
| Antibody Affinity | 4 | 2016 | 11 | 0.120 |
Why?
|
| Blood | 1 | 2015 | 51 | 0.120 |
Why?
|
| Surface Plasmon Resonance | 2 | 2011 | 4 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2019 | 39 | 0.110 |
Why?
|
| Aptamers, Peptide | 1 | 2014 | 1 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 15 | 0.110 |
Why?
|
| Cytokines | 1 | 2015 | 107 | 0.110 |
Why?
|
| Ileum | 1 | 2014 | 3 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 5 | 0.110 |
Why?
|
| Sequence Homology | 3 | 2009 | 11 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cloning, Molecular | 3 | 2013 | 26 | 0.110 |
Why?
|
| Population Surveillance | 3 | 2019 | 325 | 0.110 |
Why?
|
| Global Health | 3 | 2017 | 193 | 0.110 |
Why?
|
| Hepacivirus | 2 | 2023 | 37 | 0.110 |
Why?
|
| Microbiota | 1 | 2014 | 30 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 8 | 0.110 |
Why?
|
| DNA, Viral | 4 | 2009 | 165 | 0.110 |
Why?
|
| Placebos | 3 | 2019 | 44 | 0.110 |
Why?
|
| Drug Tolerance | 1 | 2013 | 2 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 244 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 3 | 0.100 |
Why?
|
| Genetic Vectors | 4 | 2020 | 55 | 0.100 |
Why?
|
| Mice | 3 | 2021 | 135 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2018 | 48 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2016 | 13 | 0.100 |
Why?
|
| Tanzania | 3 | 2021 | 88 | 0.100 |
Why?
|
| Breast Feeding | 2 | 2019 | 120 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 32 | 0.090 |
Why?
|
| Chimera | 2 | 2008 | 3 | 0.090 |
Why?
|
| Fluorescein | 1 | 2011 | 1 | 0.090 |
Why?
|
| Guinea Pigs | 3 | 2021 | 11 | 0.090 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 196 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 11 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2010 | 411 | 0.090 |
Why?
|
| Antigens | 2 | 2022 | 11 | 0.090 |
Why?
|
| Benzoxazines | 1 | 2011 | 123 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2010 | 14 | 0.080 |
Why?
|
| Sex Work | 3 | 2008 | 39 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 25 | 0.080 |
Why?
|
| DNA | 2 | 2021 | 73 | 0.080 |
Why?
|
| Seroepidemiologic Studies | 2 | 2025 | 109 | 0.080 |
Why?
|
| Antibody Diversity | 1 | 2009 | 2 | 0.080 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 103 | 0.080 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Adsorption | 1 | 2009 | 6 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 279 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 45 | 0.080 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2009 | 9 | 0.080 |
Why?
|
| Protein Domains | 2 | 2020 | 10 | 0.080 |
Why?
|
| HeLa Cells | 3 | 2017 | 15 | 0.080 |
Why?
|
| Immunity, Humoral | 2 | 2019 | 42 | 0.080 |
Why?
|
| International Cooperation | 3 | 2019 | 50 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2008 | 24 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2006 | 16 | 0.070 |
Why?
|
| Americas | 2 | 2021 | 10 | 0.070 |
Why?
|
| Protein Subunits | 2 | 2021 | 4 | 0.070 |
Why?
|
| Europe | 2 | 2021 | 56 | 0.070 |
Why?
|
| Injections, Intramuscular | 2 | 2020 | 31 | 0.070 |
Why?
|
| Tuberculosis, Meningeal | 2 | 1998 | 10 | 0.070 |
Why?
|
| HIV Seroprevalence | 1 | 2008 | 15 | 0.070 |
Why?
|
| Sequence Analysis, Protein | 3 | 2018 | 10 | 0.070 |
Why?
|
| Aged | 2 | 2025 | 1740 | 0.070 |
Why?
|
| Virulence | 1 | 2007 | 25 | 0.070 |
Why?
|
| Protein Engineering | 2 | 2020 | 7 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 112 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 71 | 0.070 |
Why?
|
| Valine | 1 | 2007 | 6 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2008 | 89 | 0.070 |
Why?
|
| Laboratories | 1 | 2008 | 47 | 0.070 |
Why?
|
| Incidence | 3 | 2021 | 685 | 0.070 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 28 | 0.070 |
Why?
|
| Giant Cells | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 6 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2013 | 107 | 0.060 |
Why?
|
| Proviruses | 1 | 2006 | 6 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2008 | 132 | 0.060 |
Why?
|
| Macaca | 2 | 2018 | 4 | 0.060 |
Why?
|
| Milk, Human | 1 | 2006 | 23 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2006 | 20 | 0.060 |
Why?
|
| Thailand | 2 | 2019 | 26 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 40 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2017 | 4 | 0.060 |
Why?
|
| Sperm Motility | 1 | 2005 | 1 | 0.060 |
Why?
|
| Trypsin | 1 | 2005 | 2 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 49 | 0.060 |
Why?
|
| Semen | 1 | 2005 | 3 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 179 | 0.060 |
Why?
|
| Sentinel Surveillance | 2 | 2017 | 115 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 6 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 114 | 0.060 |
Why?
|
| Zambia | 2 | 2021 | 115 | 0.060 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 2 | 2016 | 4 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2005 | 7 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2005 | 19 | 0.060 |
Why?
|
| Transcriptome | 1 | 2024 | 14 | 0.060 |
Why?
|
| Genes, Viral | 1 | 2004 | 11 | 0.060 |
Why?
|
| Computational Biology | 2 | 2016 | 44 | 0.060 |
Why?
|
| Gels | 2 | 2015 | 19 | 0.060 |
Why?
|
| Immunologic Memory | 2 | 2016 | 15 | 0.050 |
Why?
|
| Antigens, Viral | 2 | 2018 | 21 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 10 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2023 | 80 | 0.050 |
Why?
|
| Benzylamines | 1 | 2003 | 1 | 0.050 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 4 | 0.050 |
Why?
|
| Heterocyclic Compounds | 1 | 2003 | 3 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2003 | 53 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 29 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 54 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 125 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 56 | 0.050 |
Why?
|
| Solvents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Immunoglobulin Allotypes | 1 | 2022 | 1 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 10 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 26 | 0.050 |
Why?
|
| Myocytes, Cardiac | 2 | 2014 | 8 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2003 | 77 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 49 | 0.050 |
Why?
|
| Algorithms | 2 | 2017 | 106 | 0.050 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2021 | 2 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 50 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 5 | 0.050 |
Why?
|
| SARS Virus | 1 | 2021 | 1 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 4 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 106 | 0.040 |
Why?
|
| AIDS Dementia Complex | 2 | 1999 | 29 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 13 | 0.040 |
Why?
|
| Tretinoin | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 45 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 33 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 11 | 0.040 |
Why?
|
| Lamivudine | 2 | 2011 | 89 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 16 | 0.040 |
Why?
|
| Stavudine | 2 | 2011 | 78 | 0.040 |
Why?
|
| Malawi | 2 | 2013 | 87 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2020 | 2 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 4 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2020 | 4 | 0.040 |
Why?
|
| Plasmids | 1 | 2020 | 23 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 10 | 0.040 |
Why?
|
| Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
|
| Arthralgia | 1 | 2020 | 4 | 0.040 |
Why?
|
| Headache | 1 | 2020 | 7 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2013 | 22 | 0.040 |
Why?
|
| Marketing of Health Services | 1 | 2019 | 2 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 12 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 11 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 353 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2019 | 4 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Lactation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 20 | 0.040 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 329 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Activins | 1 | 2019 | 3 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 3 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 9 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 7 | 0.040 |
Why?
|
| Rabbits | 1 | 2019 | 35 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 85 | 0.040 |
Why?
|
| Epidemics | 1 | 2019 | 65 | 0.040 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 10 | 0.040 |
Why?
|
| Neurosyphilis | 1 | 1998 | 1 | 0.040 |
Why?
|
| Models, Biological | 2 | 2009 | 77 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 34 | 0.040 |
Why?
|
| Meningitis, Bacterial | 1 | 1999 | 38 | 0.040 |
Why?
|
| Meningitis, Cryptococcal | 1 | 1998 | 16 | 0.040 |
Why?
|
| RNA | 1 | 2018 | 26 | 0.040 |
Why?
|
| Meningitis, Fungal | 1 | 1998 | 1 | 0.040 |
Why?
|
| Meningitis, Aseptic | 1 | 1998 | 2 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cell Communication | 1 | 2018 | 3 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1998 | 24 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1998 | 20 | 0.040 |
Why?
|
| HIV Core Protein p24 | 1 | 1998 | 18 | 0.040 |
Why?
|
| Cryptococcosis | 1 | 1998 | 17 | 0.040 |
Why?
|
| Meningitis, Meningococcal | 1 | 1998 | 17 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 1998 | 24 | 0.040 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 6 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 370 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 4 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 280 | 0.030 |
Why?
|
| Sexual Behavior | 2 | 2010 | 320 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2016 | 1 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 125 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 49 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 20 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 73 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 42 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 10 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 34 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2016 | 2 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 25 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 34 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1999 | 324 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 2015 | 2 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 8 | 0.030 |
Why?
|
| Namibia | 1 | 2015 | 19 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 1475 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 47 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 72 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 10 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 2015 | 44 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 239 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2014 | 1 | 0.030 |
Why?
|
| Membrane Fusion | 1 | 2014 | 1 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2014 | 1 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Macrophages | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immune Sera | 1 | 2014 | 1 | 0.030 |
Why?
|
| Proteolipids | 1 | 2014 | 1 | 0.030 |
Why?
|
| Neutron Diffraction | 1 | 2014 | 1 | 0.030 |
Why?
|
| Scattering, Small Angle | 1 | 2014 | 1 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 4 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 32 | 0.030 |
Why?
|
| Apoptosis | 1 | 2014 | 40 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 32 | 0.030 |
Why?
|
| Fluconazole | 1 | 2014 | 17 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 33 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 149 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 376 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2014 | 40 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2013 | 2 | 0.030 |
Why?
|
| Serum | 1 | 2013 | 9 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 1 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 227 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 23 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 20 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.020 |
Why?
|
| Point Mutation | 1 | 2012 | 16 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 52 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 111 | 0.020 |
Why?
|
| Alkynes | 1 | 2011 | 117 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2011 | 123 | 0.020 |
Why?
|
| Zidovudine | 1 | 2011 | 59 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 29 | 0.020 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2011 | 3 | 0.020 |
Why?
|
| Receptors, Lipoxin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 370 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 77 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 151 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 105 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 16 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2010 | 50 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2009 | 4 | 0.020 |
Why?
|
| Receptors, CXCR5 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 117 | 0.020 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 1 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2009 | 11 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2009 | 4 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 31 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 48 | 0.020 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2009 | 33 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 105 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 6 | 0.020 |
Why?
|
| India | 1 | 2009 | 62 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2008 | 19 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 257 | 0.020 |
Why?
|
| Prognosis | 1 | 2008 | 199 | 0.020 |
Why?
|
| Accreditation | 1 | 2008 | 3 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 87 | 0.020 |
Why?
|
| Program Development | 1 | 2008 | 32 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 101 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 43 | 0.020 |
Why?
|
| Condoms | 1 | 2008 | 88 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2008 | 121 | 0.020 |
Why?
|
| Cote d'Ivoire | 1 | 2007 | 6 | 0.020 |
Why?
|
| Research Design | 1 | 2008 | 124 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 7 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2007 | 120 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 127 | 0.020 |
Why?
|
| Heterosexuality | 1 | 2006 | 30 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2006 | 3 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 9 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 12 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2006 | 6 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2006 | 1 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2006 | 2 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2006 | 14 | 0.020 |
Why?
|
| Rural Population | 1 | 2010 | 654 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 34 | 0.020 |
Why?
|
| RNA Interference | 1 | 2006 | 45 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2005 | 1 | 0.020 |
Why?
|
| Denmark | 1 | 2005 | 1 | 0.020 |
Why?
|
| Quebec | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cattle | 1 | 2005 | 28 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 188 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 217 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 2005 | 6 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2005 | 30 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 31 | 0.010 |
Why?
|
| Africa, Southern | 1 | 2005 | 91 | 0.010 |
Why?
|
| South America | 1 | 2004 | 27 | 0.010 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 54 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 6 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 133 | 0.010 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Vero Cells | 1 | 2003 | 6 | 0.010 |
Why?
|
| Replicon | 1 | 2003 | 2 | 0.010 |
Why?
|
| Spinal Puncture | 1 | 1999 | 4 | 0.010 |
Why?
|
| Tuberculoma | 1 | 1998 | 1 | 0.010 |
Why?
|
| Gold | 1 | 1999 | 38 | 0.010 |
Why?
|
| Mining | 1 | 1999 | 41 | 0.010 |
Why?
|